USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AZEVAN PHARMACEUTICALS, INC.
Address:
116 RESEARCH DRIVE
BETHLEHEM, PA
Phone:
(610) 758-3620
URL:
N/A
EIN:
142167269
DUNS:
604182118
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $449,195.00 2
SBIR Phase II $1,794,075.00 2
STTR Phase I $241,071.00 3
STTR Phase II $498,684.00 1

Award List:

N/A

Award Year / Program / Phase:
2000 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Neal Simon, Principal Investigator
Research Institution:
Lehigh University
RI Contact:
N/A
Abstract:
N/a

A NEW DRUG FOR DEPRESSION

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and has refined these molecules through manipulations of various structural zones. A subset of these… More

A Potential New Drug for Depression

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): A Potential New Drug for Depression, an active SBIR Phase IIa award. The requested funds will allow additional characterization studies of three newly discovered mixed vasopressin 1a/1b antagonists, studies that were not part of the original application. These… More

New Drugs for Stress-related Affective Illness

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$349,195.00
Agency:
HHS
Principal Investigator:
Michael Brownstein
Abstract:
DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observations in depressed individuals, findings in animal mode ls, and an understanding of changes in… More

Screening New Therapeutics for the Treatment of Post Traumatic Stress Disorder

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$141,071.00
Agency:
HHS
Principal Investigator:
Neal G. Simon – 610-758-3620
Research Institution:
NORTHEASTERN UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Project Summary/Abstract Post-traumatic Stress Disorder (PTSD) is recognized by the NIMH, the Department of Defense, and the Veterans' Administration as a major medical issue. Recent studies indicate that the incidence of PTSD among Iraq and Afghanistan… More

New Drugs for Stress-related Affective Illness

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,794,075.00
Agency:
HHS
Principal Investigator:
Michael Brownstein – 610-419-1057
Abstract:
DESCRIPTION (provided by applicant): Vasopressin (AVP) antagonists represent a novel therapeutic class for the treatment of depression. The potential utility of these compounds has emerged from observations in depressed individuals, findings in animal models, and an understanding of changes in… More